CD BioGlyco's advanced glycosylation inhibitor development platforms closely follow the development trend in science and technology. We aim to provide customers with unparalleled support services for glycosylation research. We have confidence to be your essential research assistant in the field of glycobiology.
After genomics and proteomics, glycomics has gradually become a new research field. Glycosylation is a significant post-translational modification. Its role is vital in various life processes, such as cell growth and reproduction, adhesion, and signal transduction. Abnormal glycosylation usually leads to the occurrence of some diseases. For example, I-cell disease is the first disease identified as abnormal glycosylation because the N-sugar chain cannot be further modified by mannose-6-phosphate. In cystic fibrosis, abnormal glycosylation has also been confirmed: fucose increases and sialic acid decreases. Therefore, the research of glycosylation has become a hot spot both in fundamental science and clinical applications. Glycosylation inhibitors have also begun to be used in treating diseases. For example, Miglitol has been used in the treatment of diabetes. N-Butyldeoxynojirimycin has also been used in clinical trials for the treatment of Gaucher disease.
Glycosylation inhibitors can make up for the defects of mutants in research, that is, the latter requires tedious steps to isolate mutant cells or organisms, and many mutations are fatal in animals. Therefore, inhibitors provide another feasible method for studying glycosylation in cells and organisms. At present, a variety of glycosylation inhibitors have been developed, including natural products, substrate-based tight-binding inhibitors, glycoside primers, inhibitors discovered by screening chemical libraries, and inhibitors rationally designed based on the three-dimensional structure of the related enzyme. Most of these compounds are small molecules, so they are easily absorbed by cells, which provides an opportunity to design drugs for the treatment of diseases related to altered glycosylation.
Fig 1. Exo- and endo-acting glycoside hydrolases can be inhibited by carbohydrate-based and medicinal chemistry-based inhibitors (Gloster, T.M.; Vocadlo, D.J. 2012)
Our team of scientists has many years of experience in the development of glycosylation inhibitors. With our various advanced technology platforms, we are able to provide customers with strong support for inhibitor development. Our glycosylation inhibitor development services include but are not limited to the following directions.
Natural glycosylation inhibitors may be found in plants, fungi and bacteria, and are part of a chemical defense strategy against other competing organisms in the same ecosystem.
Block glycosylation by interfering with the common precursor metabolism or intracellular transport activities.
Based on the concept that substrate analogs can act as tight-binding competitive inhibitors.
Glycoside primers act as inhibitors of glycoprotein and proteoglycan assembly by disrupting the cellular machinery used to produce oligosaccharides on endogenous proteins.
Compounds designed using the three-dimensional structure analysis of the physical and chemical properties of the binding site can have higher specificity.
CD BioGlyco provides systematic overall solutions for the development of glycosylation inhibitors. Our experimental schemes are formulated by experts with many years of experience in this field. Our broad vision can provide customers with professional and high-quality help for scientific research projects.
Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.
References:
About Us
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
Contact Us
